Fig. 2

ICV DFX reduces cerebral inflammatory milieu after SAH—hematogenous and cerebral myeloid cell populations, cerebral IL-6 concentration, and cerebral mitochondrial superoxide anion were measured in the following treatment groups on POD7 in WT mice: SAH sham + vehicle, SAH + vehicle, SAH + IP DFX, and SAH + ICV DFX. a Flow cytometry of hematogenous cell populations show no significant change between any of the groups (one-way ANOVA; n = 4 per group). b Flow cytometry of cerebral myeloid cell populations show a trend towards increase in the microglia/macrophage populations of the SAH + vehicle group versus the SAH sham + vehicle group; but no significant changes between any of the other groups (one-way ANOVA; n = 4 per group). c Cerebral IL-6 concentration as measured by ELISA was significantly increased in the SAH + vehicle group (*P < 0.05 versus the SAH sham + vehicle group) and markedly decreased in the SAH + ICV DFX group (*P < 0.05 versus the SAH + vehicle group) (one-way ANOVA P < 0.05; n = 4 per group). d Cerebral mitochondrial superoxide anion (MitoSox) positive cells measured by flow cytometry did not show significant decrease in the SAH + ICV DFX group versus the SAH + vehicle group and the SAH + IP DFX group (one-way ANOVA P < 0.05; n = 4 per group). e Representative flow cytometry dot plots from each group. The Q3 percentage (shown) represents the percentage of cells positive for MitoSOX red